Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liquid biopsy for molecular profiling in cutaneous T-cell lymphoma: a pilot feasibility study.

Blood neoplasia·2026
Same author

Serum proteomic and single-cell transcriptomic profiling reveals immunoproteomic features distinguishing early-stage mycosis fungoides from atopic dermatitis.

The Journal of investigative dermatology·2026
Same author

Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

Leukemia & lymphoma·2026
Same author

SOHO State of the Art Updates and Next Questions | Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?

Clinical lymphoma, myeloma & leukemia·2026
Same author

Staging imaging reveals clinically significant comorbidities in primary cutaneous marginal zone lymphoma: A retrospective study.

Journal of the American Academy of Dermatology·2026
Same author

Cutaneous B-Cell lymphoma incidence trends in the United States: A surveillance, epidemiology, and end results analysis of 10,975 cases.

The Journal of investigative dermatology·2026

Related Experiment Video

Updated: May 4, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K

Brentuximab Vedotin in CD30+ Lymphomas.

Guilherme Fleury Perini1, Barbara Pro2

  • 1Hospital Israelita Albert Einstein, Sao Paulo, SP Brazil.

Biologics in Therapy
|January 7, 2014
PubMed
Summary

Monoclonal antibodies targeting CD30 show promise for treating hematologic cancers. Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, effectively targets malignant cells in Hodgkin

Keywords:
Anaplastic large-cell lymphomaAntibody-drug conjugateBrentuximab vedotinCD30Hodgkin’s lymphomaMonomethylauristatin EOncology

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Related Experiment Videos

Last Updated: May 4, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Hematologic malignancies, including classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL), are challenging to treat.
  • CD30 is a highly expressed target on malignant cells in cHL and ALCL with limited expression on normal tissues, making it an ideal therapeutic target.

Approach:

  • Development of Brentuximab vedotin, an antibody-drug conjugate (ADC) that links a monoclonal antibody (mAb) targeting CD30 to a potent cytotoxic agent.
  • Utilizing the specific targeting of mAbs to deliver cytotoxic payloads directly to CD30-expressing cancer cells, minimizing systemic toxicity.

Key Points:

  • Brentuximab vedotin demonstrates significant clinical activity in patients with relapsed or refractory cHL and ALCL.
  • The anti-CD30 antibody-drug conjugate mechanism allows for targeted delivery of chemotherapy, enhancing efficacy.
  • CD30-targeted therapy offers a promising strategy for difficult-to-treat hematologic cancers.

Conclusions:

  • Brentuximab vedotin represents a significant advancement in the treatment of relapsed or refractory cHL and ALCL.
  • Targeted antibody-drug conjugate therapy holds potential for improving outcomes in hematologic oncology.
  • The efficacy of Brentuximab vedotin highlights the therapeutic value of targeting CD30 in specific hematologic malignancies.